drugset
drugset / Trial / NCT03396471

Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary

NCT03396471 ↗

Phase 2 Terminated 14 enrolled Hoosier Cancer Research Network Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

Single-arm phase 2 study to examine pembrolizumab and concurrent radiation to induce an abscopal effect in patients with previously treated carcinoma of unknown primary (CUP16-268)

Timeline

Start
2018-02-01
Primary completion
2021-08-12
Completion
2023-03-02

Outcome

Outcome not reported

Stopped: “Study failed to meet its interim analysis endpoint”

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

cancer of unknown primary site